TT-53

TT-53 is a **small-molecule dual antagonist of the adenosine A2A and A2B receptors** being developed for cancer immunotherapy, particularly **solid tumors**. The program originated at Tarus Therapeutics and was later acquired by Portage Biotech, which renamed the asset **PORT-8**. By blocking the immunosuppressive adenosine signaling axis in the tumor microenvironment, TT-53 is intended to restore anti-tumor immune activity and improve responses in adenosine-rich tumors. Public pipeline materials describe it as part of Portage's adenosine receptor inhibitor portfolio, but more recent summaries indicate the program is no longer being actively developed.